US2215233A - Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same - Google Patents

Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same Download PDF

Info

Publication number
US2215233A
US2215233A US174484A US17448437A US2215233A US 2215233 A US2215233 A US 2215233A US 174484 A US174484 A US 174484A US 17448437 A US17448437 A US 17448437A US 2215233 A US2215233 A US 2215233A
Authority
US
United States
Prior art keywords
nucleotides
iron
organic
decomposition products
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US174484A
Inventor
Simon L Ruskin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US174484A priority Critical patent/US2215233A/en
Application granted granted Critical
Publication of US2215233A publication Critical patent/US2215233A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds

Definitions

  • This invention relates to organic compoun of iron and more particularly to therapeutic preparations containing iron compounds of nu-;
  • a further object of the invention is to provide a method for producing iron compounds of nu-,
  • cleotides or their organic hydrolytic decomposipyrimidine ring such as the nucleosides, or the purine and pyrimidine bases derived therefrom.
  • Another object of this invention is to provide a method whereby insoluble or diflicultly soluble compounds of iron with nucleotides or their organic hydrolitic decomposition products which contain a pyrimidine ring, such as the nucleosides, or the purine and pyrimidine bases derived therefrom may be brought into solution to enable them to be administered internally in high concentration, either by injection or per os.
  • nucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring, such as the nucleosides, or the purine and pyrimidine bases derived therefrom are to be understood compounds which are obtained or are obtainable from nucle oproteins by hydrolysis.
  • the nucleotides are composed of nucleosides and phosphoric acid and are acids; they are decomposed by the action of hot water, ferments, acids or alkalies.
  • the mononucleotides can be isolated from pancreas and from extract of meat as well as from yeast and also other substances in any known manner.
  • the nucleosides which, in combination with phosphoric acid, form the nucleotides, are glucosides of various purine and pyrimidine bases. They are obtained by the action of ferments and are finally decomposed into the various purine and pyrimidine bases, of which the following may be mentioned: thymin, cytosin, uracil, adenin and guanin. These final hydrolytic decomposition products have also been produced directly from nucleoproteins, nucleins and nucleotides by the action of acids or alkalies.
  • the invention comprises .not only the compounds as obtained by hydrolytic decompostion of nucleoproteins, but also those compounds which are produced synthetically, i. e., in the reverse order of the table.
  • nucleic acid is radically different from the larger molecule, the nucleic acid,. not merely in chemical constitution but 'in specific physiologic actions.
  • purine nucleotides on the one hand, and the pyrimidine nucleotides on the other, while they bothconta'in a are more or less opposites of each other, and the same is true of the pyrimidine nucleotides.
  • the more specific virtue of the iron salts of the purine nucleotides lies in their ability to elevate thewhole blood picture; that is, the haemoglobin content and the redblood cell (erythrocyte) and white blood cell (leucocyte) counts are increased.
  • This is unique, since the action of known therapeutic iron salts is to elevate only the haemoglobin and red blood cell count.
  • the supplementary action of the purine nucleotide portion of the salt elevates the white blood cell count.
  • Another important advantage resulting from the use of these combinations of iron and nucleotides or their organic hydrolytic decomposition products therapeutically is that they have a very great stimulating effect upon the reticulo-endothelial system, so that they are of great value in the treatment of diseases caused by deficiencies of this system, such as agranulocytosis, benzene poisoning, X-ray poisoning and various leucopenias incident to exhaustion of the reticuluendothelial systems.
  • Ferrous adenylate may be made in the following manner. grams of adenylic acid are suspended in approximatelyBOO cc. of water and neutralized with ammonia. grams of ferrous ammonium sulphate are dissolved in about 200 cc. of water. In order to be certain that all the iron is in the ferrous state, a few drops of sulphuric acid are added and also a small amount of iron filings. This solution is then agitated, filtered and added to the solution of adenylic acid. A precipitate of ferrous adenylate or guanylate is obtained. Approximately 500 cc. of alcohol are now added. The mixture is then allowed to stand for a couple of hours during which time coagulation and settling takes place. The ferrous adenylate is then filtered off with the aid of such. The ferrous adenylate is sludged up in about 300 cc. of water, an equal quantity Internal Medicine, vol. 9,
  • the ferrous adenylate may be used in tablet form or dissolved with the addition of sodium citrate and put in ampoule form for injection or in bottles for administration per os.
  • ferrous chloride may be used, in which case it is desirable to employ sodium adenylate (or guanylate, etc.) as sodium chloride is then produced which need not be separated from the iron nucleotide.
  • guanylate cytidilate, and uridylate may be produced in a similar manner from the corresponding nucleotides.
  • starting material may be used the alkali-metal salts of the purine or pyrimidine nucleotides or their organic hydrolytic decomposition products which contain a pyrimidine ring and are capable of combining with iron.
  • Separation of the crude precipitate, as well as of the purified compound may be carried out in any suitable manner, by filtering, centrifuging, pressing through a filter press, decanting or in any other suitable way.
  • Suspension of the crude product in water, in order to purify it may also be accomplished by extracting the precipitate in suitable extraction apparatus, by macerating or by any other suitable method, while stirring or shaking at ordinary or elevated temperature. Extraction is especially advisable in the case of themore diflicultly soluble compounds of mononucleotides.
  • sodium citrate instead of sodium citrate, other salt solutions, such as potassium acetate or citrate, sodium chloride, sodium nitrate, sodium acetate, ammonia citrate and others may be used for solubilizing insoluble or difllcultly soluble compounds.
  • salt solutions such as potassium acetate or citrate, sodium chloride, sodium nitrate, sodium acetate, ammonia citrate and others may be used for solubilizing insoluble or difllcultly soluble compounds.
  • benzene, ether or any other organic liquid in which the iron compound produced is insoluble may be employed.
  • the drying may be effected at ordinary or elevated temperature, in a vacuum or by means of an air current or in any other suitable manner, care being taken that the conditions are not such that the iron compound is decomposed.
  • reaction products of the organic and inorganic iron compounds on the one hand and nucleoproteins, nucleotides and their hydrolytic decomposition products on the other hand can be purified in another manner than by redissolving or suspending and re-precipitating, e. g., by recrystallization, or by any other suitable method.
  • ferric compounds are also of value; and generally, although not necessarily, a certain amount of the ferric will accompany the ferrous compound or compounds.
  • the individual, isolated iron nucleotides may be used singly, or they may be used in the form of two isolated nucleotides, especially where it is desired to suppress one or more actions of a nucleotide, in which case a nucleotide having an opposite action is used simultaneously.
  • two pyrimidine or two purine nucleotides may be used simultaneously; and for certain purposes an isolated pyrimidine iron compound may with advantage be mixed with an isolated purine iron compound.
  • the iron compounds above described may be administered either orally or subcutaneously.
  • intramuscular injection is preferred; the dosage is about to 2 grains of the iron compound by injection ⁇ funds of the organic substances above men- 8,215,288 daily or every two days; while orally from 5 to 10 grams or more may be administered as often as three times a day, depending on the tolerance of the stomach and requirements of the patient.
  • the free nucleotides may be reacted with iron compounds, including basic iron compounds to produce the iron nucleotides.
  • a medicinal preparation for the treatment of diseases by application to the human or animal body comprising a. solubilized iron compound of isolated adenylic acid.
  • a medicinal preparation for the treatment of diseases by application to the human or animalbody comprising the isolated adenylic acid compound of ferrous iron.
  • a medicinal preparation for the treatment of diseases by application to the human or animal body comprising an iron compound 0! an isolated mononucleotide and a solubilizing agent therefor comprising an alkali metal salt of an organic acid.
  • a therapeutic preparation comprising the combination of ferrous iron and a compound selected from the group consisting of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule and which are capable of combining with iron, said combination being soluble in water and in organic salt solutions.
  • a method of producing iron compounds of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule consisting in reacting a compound selected from the group of compounds consisting of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule, with an aqueous solution of an iron salt, separating the precipitated reaction product from the mother liquor, dissolving said precipitate in an aqueous solution with the aid of a salt of the group consisting of sodium citrate, ammonium citrate, sodium chloride, sodium nitrate,- and the corresponding potassium salts.
  • a medicinal preparation comprising the reaction product of a ferrous compound and a member of the group consisting of free and neutralized adenylic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

- tion products which contain a PATENT OFFICE IRON COMPOUND THEIR ORGANIC POSITION PROD MAKING SAME or NUCLEOTIDES AND nrnnommc DECOM- ors Ann MErnon 0F Simon L. Ruskin, New York, N. Y.
No Drawing. ApplicationNovember13,1937,
SerlalNo. 174,484
16 Claims.
This invention relates to organic compoun of iron and more particularly to therapeutic preparations containing iron compounds of nu-;
cleotides and their organic hydrolytic decomposition products which contain a. pyrimidine ring in their molecule. The present application is a continuation in part of my copending applications Serial No. 650,137, filed January 4, 1933, now Patent No. 2,115,751 of May 3, 1938, and Serial Nos. 696,388 and 696,390, filed November 2, 1933, the latter having issued as Patent No. 2,098,976 of Nov. 16, 1937.
It is an object of the invention to provide a therapeutic preparation containing ahigh proportion of iron and possessing desirable therapeutic activity when administered into the animal organism.
A further object of the invention is to provide a method for producing iron compounds of nu-,
cleotides or their organic hydrolytic decomposipyrimidine ring, such as the nucleosides, or the purine and pyrimidine bases derived therefrom.
Another object of this invention is to provide a method whereby insoluble or diflicultly soluble compounds of iron with nucleotides or their organic hydrolitic decomposition products which contain a pyrimidine ring, such as the nucleosides, or the purine and pyrimidine bases derived therefrom may be brought into solution to enable them to be administered internally in high concentration, either by injection or per os.
Under the expression fnucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring, such as the nucleosides, or the purine and pyrimidine bases derived therefrom are to be understood compounds which are obtained or are obtainable from nucle oproteins by hydrolysis. The nucleotides are composed of nucleosides and phosphoric acid and are acids; they are decomposed by the action of hot water, ferments, acids or alkalies. The mononucleotides can be isolated from pancreas and from extract of meat as well as from yeast and also other substances in any known manner.
The nucleosides which, in combination with phosphoric acid, form the nucleotides, are glucosides of various purine and pyrimidine bases. They are obtained by the action of ferments and are finally decomposed into the various purine and pyrimidine bases, of which the following may be mentioned: thymin, cytosin, uracil, adenin and guanin. These final hydrolytic decomposition products have also been produced directly from nucleoproteins, nucleins and nucleotides by the action of acids or alkalies.
As the chemical constitution and the nomenclature of the more complex organic compounds employed in the process of this invention are still in a state of considerable confusion, the following table is presented to give a clearer picture of the scope of the'invention and of the relationship existing between allthese compounds:
Albumen H Nucleoprotein Albumen MIXTURES OF #UQLEOTIDEB MONONUCLEOTIDES (e. g. ADENYLIO, Phosphoric we GUANYLIC, etc.,
ACIDS) Carbohydrates M NUCLEOSIDES (Hexoses (GLUCOSIDES) Pentoscsj I PYRIMIDIN E DERIVATIVES PURINE (e. 3., THYMIN, DE RIVATIVES C YTOSIN, g., URACIL) GUANIN, XANTHIN, HYPOXAN THIN ADENIN) Of course, the invention comprises .not only the compounds as obtained by hydrolytic decompostion of nucleoproteins, but also those compounds which are produced synthetically, i. e., in the reverse order of the table.
If we group the nucleotides in accordance with their physiologic action, we get a schematic ar-. rangement as follows:
ANALYSES 0] N UGLEO'IIDE ACTION leukocytosis. Ingreases coronary circula- Participates in carbohydrate metabolism.
. Participates in muscle metabolism.
2. Iniuces leukopenia on injecon. 3. Inhibits bacterial growth. 4. Is antiseptic in stronger diluions.
5. Acts like barbiturates on metabolism.
. Acts as a coenzyzme.
. Is a glandular stimulant.
It will readily be seen that the individual nucleotides are radically different from the larger molecule, the nucleic acid,. not merely in chemical constitution but 'in specific physiologic actions. It will be noted that the purine nucleotides on the one hand, and the pyrimidine nucleotides on the other, while they bothconta'in a are more or less opposites of each other, and the same is true of the pyrimidine nucleotides. I have found that advantage 'can be taken of the specific physiologic actions of the different nucleotides and of their pyrimidine-ring containing decomposition products by combining them with iron, either ferrous or ferric, the resulting compounds, probably because of their close relationship to substances naturally present in the animal tissues, representing also excellent media for the introduction of iron into the organism.
The more specific virtue of the iron salts of the purine nucleotides lies in their ability to elevate thewhole blood picture; that is, the haemoglobin content and the redblood cell (erythrocyte) and white blood cell (leucocyte) counts are increased. This is unique, since the action of known therapeutic iron salts is to elevate only the haemoglobin and red blood cell count. The supplementary action of the purine nucleotide portion of the salt elevates the white blood cell count. In addition, there is a remarkable synergistic action between the adenylic nucleotides and the haemoglobin and red blood cells. Thus there is always a direct ratio between the adenylic acid content of the blood and the haemoglobin and the red blood cell count. When the adenylic acid content of the blood is high, there is a high haemoglobin and red cell count. Inversely, where the haemoglobin and red cell count is low, there is a low adenylic acid content. Thus ferrous adenylate or guanylate presents a highly desirable and unique therapeutic preparation.
Another important advantage resulting from the use of these combinations of iron and nucleotides or their organic hydrolytic decomposition products therapeutically is that they have a very great stimulating effect upon the reticulo-endothelial system, so that they are of great value in the treatment of diseases caused by deficiencies of this system, such as agranulocytosis, benzene poisoning, X-ray poisoning and various leucopenias incident to exhaustion of the reticuluendothelial systems.
The clinical application of this product has been demonstrated and the results obtained are published in Annals of No. 11, May 1936.
For the purpose of illustrating my invention in greater detail and by way of example, I will describe the preparation of the combination of iron with adenylic nucleotide.
Ferrous adenylate may be made in the following manner. grams of adenylic acid are suspended in approximatelyBOO cc. of water and neutralized with ammonia. grams of ferrous ammonium sulphate are dissolved in about 200 cc. of water. In order to be certain that all the iron is in the ferrous state, a few drops of sulphuric acid are added and also a small amount of iron filings. This solution is then agitated, filtered and added to the solution of adenylic acid. A precipitate of ferrous adenylate or guanylate is obtained. Approximately 500 cc. of alcohol are now added. The mixture is then allowed to stand for a couple of hours during which time coagulation and settling takes place. The ferrous adenylate is then filtered off with the aid of such. The ferrous adenylate is sludged up in about 300 cc. of water, an equal quantity Internal Medicine, vol. 9,
of alcohol is added, and the mixture filtered. The
precipitate is then dried in a desiccator.
'The ferrous adenylate may be used in tablet form or dissolved with the addition of sodium citrate and put in ampoule form for injection or in bottles for administration per os.
In place of the ferrous ammonium sulphate, ferrous chloride may be used, in which case it is desirable to employ sodium adenylate (or guanylate, etc.) as sodium chloride is then produced which need not be separated from the iron nucleotide.
Other compounds than the adenylate, for example, the guanylate cytidilate, and uridylate may be produced in a similar manner from the corresponding nucleotides. As starting material may be used the alkali-metal salts of the purine or pyrimidine nucleotides or their organic hydrolytic decomposition products which contain a pyrimidine ring and are capable of combining with iron. Separation of the crude precipitate, as well as of the purified compound, may be carried out in any suitable manner, by filtering, centrifuging, pressing through a filter press, decanting or in any other suitable way. Suspension of the crude product in water, in order to purify it, may also be accomplished by extracting the precipitate in suitable extraction apparatus, by macerating or by any other suitable method, while stirring or shaking at ordinary or elevated temperature. Extraction is especially advisable in the case of themore diflicultly soluble compounds of mononucleotides. A
Instead of sodium citrate, other salt solutions, such as potassium acetate or citrate, sodium chloride, sodium nitrate, sodium acetate, ammonia citrate and others may be used for solubilizing insoluble or difllcultly soluble compounds.
As a precipitating agent one may employ benzene, ether or any other organic liquid in which the iron compound produced is insoluble.
The drying may be effected at ordinary or elevated temperature, in a vacuum or by means of an air current or in any other suitable manner, care being taken that the conditions are not such that the iron compound is decomposed.
The reaction products of the organic and inorganic iron compounds on the one hand and nucleoproteins, nucleotides and their hydrolytic decomposition products on the other hand can be purified in another manner than by redissolving or suspending and re-precipitating, e. g., by recrystallization, or by any other suitable method.
While I prefer to produce the ferrous comoned, the ferric compounds are also of value; and generally, although not necessarily, a certain amount of the ferric will accompany the ferrous compound or compounds.
The individual, isolated iron nucleotides may be used singly, or they may be used in the form of two isolated nucleotides, especially where it is desired to suppress one or more actions of a nucleotide, in which case a nucleotide having an opposite action is used simultaneously. Thus, two pyrimidine or two purine nucleotides may be used simultaneously; and for certain purposes an isolated pyrimidine iron compound may with advantage be mixed with an isolated purine iron compound.
As already indicated, the iron compounds above described may be administered either orally or subcutaneously. In the latter mode, intramuscular injection is preferred; the dosage is about to 2 grains of the iron compound by injection {funds of the organic substances above men- 8,215,288 daily or every two days; while orally from 5 to 10 grams or more may be administered as often as three times a day, depending on the tolerance of the stomach and requirements of the patient.
It will be understood that the invention is not limited to the specific examples given, as modifications may be made by those skilled in the art in accordance with the principles herein seti'orth.
Thus the free nucleotides may be reacted with iron compounds, including basic iron compounds to produce the iron nucleotides.
I claim:
1. A medicinal preparation for the treatment of diseases by application to the human or animal body comprising a. solubilized iron compound of isolated adenylic acid.
2. A medicinal preparation for the treatment of diseases by application to the human or animalbody comprising the isolated adenylic acid compound of ferrous iron.
3. A medicinal preparation for the treatment of diseases by application to the human or animal body comprising an iron compound 0! an isolated mononucleotide and a solubilizing agent therefor comprising an alkali metal salt of an organic acid.
4. A therapeutic preparation comprising the combination of ferrous iron and a compound selected from the group consisting of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule and which are capable of combining with iron, said combination being soluble in water and in organic salt solutions.
5. A method of producing iron compounds of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule, consisting in reacting a compound selected from the group of compounds consisting of mononucleotides and their organic hydrolytic decomposition products which contain a pyrimidine ring in their molecule, with an aqueous solution of an iron salt, separating the precipitated reaction product from the mother liquor, dissolving said precipitate in an aqueous solution with the aid of a salt of the group consisting of sodium citrate, ammonium citrate, sodium chloride, sodium nitrate,- and the corresponding potassium salts.
6. A medicinal preparation comprising the reaction product of a ferrous compound and a member of the group consisting of free and neutralized adenylic acid.
SIMON L. RUSKIN.
US174484A 1937-11-13 1937-11-13 Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same Expired - Lifetime US2215233A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US174484A US2215233A (en) 1937-11-13 1937-11-13 Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US174484A US2215233A (en) 1937-11-13 1937-11-13 Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same

Publications (1)

Publication Number Publication Date
US2215233A true US2215233A (en) 1940-09-17

Family

ID=22636321

Family Applications (1)

Application Number Title Priority Date Filing Date
US174484A Expired - Lifetime US2215233A (en) 1937-11-13 1937-11-13 Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same

Country Status (1)

Country Link
US (1) US2215233A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653897A (en) * 1949-06-10 1953-09-29 Ernst Bischoff Company Inc Alkali metal salts of adenylic acid
US2712541A (en) * 1952-07-10 1955-07-05 Simon L Ruskin Adenosine-6-phosphoric acid and salts thereof
US2877253A (en) * 1955-08-08 1959-03-10 Schwarz Arzneimittelfabrik G M Therapeutic iron complex
US2982690A (en) * 1958-05-26 1961-05-02 Diamond Lab Injectable veterinary iron compositions
US5268365A (en) * 1988-03-11 1993-12-07 Rudolph Frederick B Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
US20030144229A1 (en) * 2000-01-14 2003-07-31 The Government Of The U.S.A., The Secretary Of The Department Of Health And Human Services Multiple CpG oligodeoxynucleotides and their use to induce an immune response
US20040171150A1 (en) * 1994-07-15 2004-09-02 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20050209184A1 (en) * 1999-04-12 2005-09-22 The Govt. Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20080027021A1 (en) * 2001-12-20 2008-01-31 The Govt. Of The U.S.A.As Represented By The Secretary Of The Dept. Of Health & Human Services Use of cpg oligodeoxynucleotides to induce angiogenesis
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653897A (en) * 1949-06-10 1953-09-29 Ernst Bischoff Company Inc Alkali metal salts of adenylic acid
US2712541A (en) * 1952-07-10 1955-07-05 Simon L Ruskin Adenosine-6-phosphoric acid and salts thereof
US2877253A (en) * 1955-08-08 1959-03-10 Schwarz Arzneimittelfabrik G M Therapeutic iron complex
US2982690A (en) * 1958-05-26 1961-05-02 Diamond Lab Injectable veterinary iron compositions
US5268365A (en) * 1988-03-11 1993-12-07 Rudolph Frederick B Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
US20040171150A1 (en) * 1994-07-15 2004-09-02 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US8309527B2 (en) 1994-07-15 2012-11-13 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7960356B2 (en) 1999-04-12 2011-06-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20050209184A1 (en) * 1999-04-12 2005-09-22 The Govt. Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8227446B2 (en) 1999-04-12 2012-07-24 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20030144229A1 (en) * 2000-01-14 2003-07-31 The Government Of The U.S.A., The Secretary Of The Department Of Health And Human Services Multiple CpG oligodeoxynucleotides and their use to induce an immune response
US7521063B2 (en) 2000-01-14 2009-04-21 The United States Of America As Represented By The Department Of Health And Human Services Multiple CPG oligodeoxynucleotides and their use to induce an immune response
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7959934B2 (en) 2001-08-14 2011-06-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US7935351B2 (en) 2001-12-20 2011-05-03 The United States Of America As Represented By The Department Of Health And Human Services Use of CPG oligodeoxynucleotides to induce angiogenesis
US20080027021A1 (en) * 2001-12-20 2008-01-31 The Govt. Of The U.S.A.As Represented By The Secretary Of The Dept. Of Health & Human Services Use of cpg oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides

Similar Documents

Publication Publication Date Title
DE3874352T2 (en) LIPOPHILE SALTS OF S-ADENOSYL-L-METHIONINE (SAM) WITH ACYLTAURINE DERIVATIVES.
JPH0741505A (en) Antiviral substance
Masamune et al. Molisch-positive Mucopolysaccharides of Gastric Cancers as Compared with the Corresponding Components of Gastric Mucosae First Report Fractionation Procedure of Gastric Cancer and Gastric Mucosa
Gale et al. Studies on bacterial amino-acid decarboxylases: 3. Distribution and preparation of codecarboxylase
DE69113978T2 (en) ANTI-HIV MEDIUM.
DE69226856T2 (en) Water soluble biotin derivatives and related therapeutic compositions
JPH01230519A (en) Use of polysulfated heparin
SU704431A3 (en) Method of prepating polysacharides posessing antitumor activity
US4614733A (en) Polysaccharides pharmaceutical compositions and the use thereof
US4629627A (en) Antiviral substance and the manufacturing method thereof
DE2137011A1 (en) Konjac mannan obtained from konjac flour, as well as its manufacture and use
US2738302A (en) Vitamin b12 analogs and processes for preparing the same
US2115751A (en) Metal compounds of nucleoproteins and of their organic hydrolytic decomposition products and method of making same
SU871721A3 (en) Method of preparing biologically active substance capable to enhance insuline secretion and to improve glucose tolerance
US2101099A (en) Manganese compounds of nucleotides and of their hydrolytic decomposition products
US2089227A (en) Quinine compounds of nucleo proteins and process for their production
Griffin et al. The liver nucleic acid incorporation of adenine-8-C14 during azo dye carcinogenesis
Macrae et al. Observations on the liver filtrate factor of the vitamin B2 complex
US2192386A (en) Insulin preparation and process
CN106336439B (en) Preparation method of calcium dibutyryl cyclic adenosine monophosphate
DE3854158T2 (en) NUCLEOSIDE ANALOG.
US3168440A (en) Stable vitamin composition
JPH03246297A (en) Ganglioside derivative and anti-hiv agent containing thereof
Gardner et al. l-Lyxoflavin
US2328729A (en) Insulin preparation